Synthesis and Evaluation of a New Series of Antileishmanial Agents

References

• P. J. Hotez, D. H. Molyneux, A. Fenwick, J. Kumaresan, S. E. Sachs, J. D. Sachs, and L. Savioli, “Control of Neglected Tropical Diseases,” The New England Journal of Medicine 357, no. 10 (2007): 1018–27.
   PubMed Web of Science ®Google Scholar
• L. Laursen, “Tropical Disease: A Neglected Cause,” Nature 533, no. 7602 (2016): S68–S69.
   PubMedGoogle Scholar
• P. Minodier, and P. Parola, “Cutaneous Leishmaniasis Treatment,” Travel Medicine and Infectious Disease 5, no. 3 (2007): 150–8.
   PubMedGoogle Scholar
• P. A. Haughan, M. L. Chance, and L. J. Goad, “Synergism in Vitro of Lovastatin and Miconazole as Anti-Leishmanial Agents,” Biochemical Pharmacology 44, no. 11 (1992): 2199–206.
   PubMed Web of Science ®Google Scholar
• P. Desjeux, “Leishmaniasis: current Situation and New Perspectives,” Comparative Immunology, Microbiology and Infectious Diseases 27, no. 5 (2004): 305–18.
   PubMed Web of Science ®Google Scholar
• Leishmaniasis http://www.who.int/leishmaniasis/burden/magnitude/burdenmagnitude/en
   Google Scholar
• P. J. Guerin, P. Olliaro, S. Sundar, M. Boelaert, S. L. Croft, P. Desjeux, M. K. Wasunna, and A. D. Bryceson, “Visceral Leishmaniasis: current Status of Control, Diagnosis, and Treatment, and a Proposed Research and Development Agenda,” Lancet Infectious Diseases 2, no. 8 (2002): 494–501.
   PubMed Web of Science ®Google Scholar
• S. Sundar, “Drug Resistance in Indian Visceral Leishmaniasis,” Tropical Medicine & International Health 6, no. 11 (2001): 849–54.
   PubMed Web of Science ®Google Scholar
• S. L. Croft, “Recent Developments in the Chemotherapy of Leishmaniasis,” Trends in Pharmacological Sciences 9, no. 10 (1988): 376–81.
   PubMed Web of Science ®Google Scholar
• J. D. Berman, “Chemotherapy for Leishmaniasis: Biochemical Mechanisms, Clinical Efficacy, and Future Strategies,” Reviews of Infectious Diseases 10, no. 3 (1988): 560–86.
   PubMedGoogle Scholar
• T. K. Jha, “Evaluation of Diamidine Compound (Pentamidine Isethionate) in the Treatment Resistant Cases of Kala-Azar Occurring in North Bihar, India,” Transactions of the Royal Society of Tropical Medicine and Hygiene 77, no. 2 (1983): 167–70. 9203(83)90058-5
   PubMed Web of Science ®Google Scholar
• S. A. Sampaio, R. M. Castro, N. L. Dillon, and J. E. Martins, “Treatment of Mucocutaneous (American) Leishmaniasis with Amphotericin B: Report of 70 Cases,” International Journal of Dermatology 10, no. 3 (1971): 179–81.
   PubMedGoogle Scholar
• S. Sundar, and M. Chatterjee, “Visceral Leishmaniasis - Current Therapeutic Modalities,” Indian Journal of Medical Research 123, no. 3 (2006): 345–52.
   PubMed Web of Science ®Google Scholar
• C. Bern, J. Adler-Moore, J. Berenguer, M. Boelaert, M. Boer, N. R. Davidson, C. Figueras, L. Gradoni, A. D. Kafetzis, K. Ritmeijer, et al. “Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis,” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 43, no. 7 (2006): 917–24.
   PubMed Web of Science ®Google Scholar
• A. Bryceson, “A Policy for Leishmaniasis with Respect to the Prevention and Control of Drug Resistance,” Tropical Medicine & International Health 6, no. 11 (2001): 928–34..
   PubMed Web of Science ®Google Scholar
• H. Iqbal, M. Ishfaq, A. Wahab, M. N. Abbas, I. Ahmad, A. Rehman, and M. Zakir, “Therapeutic Modalities to Combat Leishmaniasis: A Review,” Asian Pacific Journal of Tropical Disease 6, no. 1 (2016): 1–5.
   Google Scholar
• D. T. Hart, W. J. Lauwers, G. Willemsens, H. V. Bossche, and F. R. Opperdoes, “Perturbation of Sterol Biosynthesis by Itraconazole and Ketoconazole in Leishmania mexicana Mexicana Infected Macrophages,” Molecular and Biochemical Parasitology 33, no. 2 (1989): 123–34.
   PubMed Web of Science ®Google Scholar
• J. A. Urbina, “Lipid Biosynthesis Pathways as Chemotherapeutic Targets in Kinetoplastid Parasites,” Parasitology 114, no. 7 (1997): 91–9.
   Google Scholar
• J. P. Wali, P. Aggarwal, U. Gupta, S. Saluja, and S. Singh, “Ketoconazole in Treatment of Visceral Leishmaniasis,” The Lancet 336, no. 8718 (1990): 810–1. https://www.cabdirect.org/cabdirect/abstract/19902076066
   PubMed Web of Science ®Google Scholar
• H. M. Al-Abdely, J. R. Graybill, D. Loebenberg, and P. C. Melby, “Efficacy of the Triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in Experimental Murine Cutaneous and Visceral Leishmaniases,” Antimicrobial Agents and Chemotherapy 43, no. 12 (1999): 2910–4.
   PubMed Web of Science ®Google Scholar
• D. H. Beach, L. J. Goad, and G. G. Holz, “Effects of Antimycotic Azoles on Growth and Sterol Biosynthesis of Leishmania Promastigotes,” Molecular and Biochemical Parasitology 31, no. 2 (1988): 149–62.
   PubMed Web of Science ®Google Scholar
• J. D. Berman, “Activity of Imidazoles against Leishmania tropica in human macrophage cultures,” The American Journal of Tropical Medicine and Hygiene 30, no. 3 (1981): 566–9.
   PubMed Web of Science ®Google Scholar
• S. Croft, R. Neal, W. Pendergast, and J. H. Chan, “The Activity of Alkyl Phosphorylcholines and Related Derivatives against Leishmania donovani,” Biochemical Pharmacology 36, no. 16 (1987): 2633–6.
   PubMed Web of Science ®Google Scholar
• T. J. Mossman, “Rapid Colorimetric Assay for Cellular Growth and Survival: application to Proliferation and Cytotoxicity Assays,” Journal of Immunological Methods 65, no. 1 (1983): 55–63.
   PubMed Web of Science ®Google Scholar